Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Loading...
Embargo End Date
ICR Authors
Authors
Stewart, GD
Aitchison, M
Bex, A
Larkin, J
Lawless, C
Méjean, A
Nathan, P
Oades, G
Patard, J-J
Paul, J
Ravaud, A
Escudier, B
Renal Cross Channel Group,
Aitchison, M
Bex, A
Larkin, J
Lawless, C
Méjean, A
Nathan, P
Oades, G
Patard, J-J
Paul, J
Ravaud, A
Escudier, B
Renal Cross Channel Group,
Document Type
Journal Article
Date
2017-06-01
Date Accepted
2016-10-14
Abstract
Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
Citation
European urology, 2017, 71 (6), pp. 845 - 847
Source Title
Publisher
ELSEVIER SCIENCE BV
ISSN
0302-2838
eISSN
1873-7560
Collections
Research Team
Melanoma and Kidney Cancer